^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
02/11/2020
Excerpt:
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Excerpt:
...- Advanced or metastatic breast cancer that is HER-2 negative (HR positive or HR negative)...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Olaparib In Metastatic Breast Cancer

Excerpt:
...- Patients with hormone receptor-positive (estrogen and/or progesterone receptor-positive) disease must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy....
Trial ID:
More C2 evidence